By Adria Calatayud

AstraZeneca PLC said Monday that a Phase 3 trial to assess the potential of its Farxiga diabetes drug to treat patients with Covid-19 at risk of developing serious complications didn't achieve statistical significance for its primary target.

The trial didn't achieve statistical significance for the primary endpoint of prevention, measuring organ dysfunction and all-cause mortality, and of recovery, measuring a change in clinical status from early recovery to death, at 30 days, the British pharmaceutical giant said.

The full trial results will be presented at the American College of Cardiology Scientific Sessions in May, AstraZeneca said.

Write to Adria Calatayud at adria.calatayud@dowjones.com

(END) Dow Jones Newswires

04-12-21 0233ET